...
首页> 外文期刊>IJC Heart & Vasculature >Reduction in thrombogenic activity and thrombocytopenia after transcatheter aortic valve implantation — The ATTRACTIVE-TTAS study
【24h】

Reduction in thrombogenic activity and thrombocytopenia after transcatheter aortic valve implantation — The ATTRACTIVE-TTAS study

机译:经导管主动脉瓣植入后血栓形成活性和血小板减少症的减少— ATTRACTIVE-TTAS研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

IntroductionBleeding complications after transcatheter aortic valve implantation (TAVI) is a major problem in clinical practice. However, there is few information on thrombogenicity after TAVI. The aim of this study was to establish a monitoring of total thrombogenicity in perioperative TAVI using the Total Thrombus-formation Analysis System (T-TAS), a microchip-based flow chamber system for analysis of thrombus formation under flow condition.MethodsTwenty-three patients with severe aortic stenosis who underwent TAVI between August 2017 and March 2018 at Kumamoto university hospital were enrolled. After exclusion, data of 21 patients were analyzed. Blood samples were obtained before, 2, 7, and 30?days after TAVI. Thrombogenicity were assessed by the T-TAS to compute the area under the curve (AUC) (AR10-AUC30) in the AR chip. We also measured platelet count, high-molecular-weight von Willebrand factor (HMW-vWF) multimers, and plasma thrombopoietin. Computational fluid dynamics (CFD) analysis was performed to calculate the wall shear stress (WSS).ResultsThe AR10-AUC30levels and platelet counts were significantly lower at 2?days post-TAVI, and then increased gradually. HMW-vWF multimers, and plasma thrombopoietin, were significantly higher at 2?days post-TAVI, compared with before TAVI. CFD analysis showed that WSS of the aortic valve and posterior ascending aortic wall were significantly lower after TAVI than before-TAVI. Multivariate analysis identified max velocity measured by echocardiography, platelet count, and D-dimer as significant determinants of AR10-AUC30, representing total thrombogenicity.ConclusionsAlthough HMW-vWF multimers improved earlier after TAVI, total thrombogenic activity evaluated by T-TAS remained relatively low followed by improvement in thrombogenic activity at 30?days after TAVI.Clinical Trial Registration:https://clinicaltrials.gov. Unique identifiers:NCT03248232.
机译:简介经导管主动脉瓣植入术(TAVI)后的出血并发症是临床实践中的主要问题。但是,关于TAVI后血栓形成的信息很少。这项研究的目的是使用总血栓形成分析系统(T-TAS)建立围手术期TAVI的总血栓形成监测,这是一种基于微芯片的流室系统,用于分析血流情况下的血栓形成。方法23例研究纳入了在2017年8月至2018年3月期间于熊本大学医院接受TAVI治疗的患有严重主动脉瓣狭窄的患者。排除后,分析了21例患者的数据。在TAVI之前,2、7和30天后采集血样。通过T-TAS评估血栓形成能力,以计算AR芯片中曲线下的面积(AUC)(AR10-AUC30)。我们还测量了血小板计数,高分子量von Willebrand因子(HMW-vWF)多聚体和血浆血小板生成素。结果在TAVI后2天,AR10-AUC30水平和血小板计数明显降低,然后逐渐增加。与TAVI前相比,在TAVI后2天,HMW-vWF多聚体和血浆血小板生成素显着升高。 CFD分析显示,TAVI后主动脉瓣和后升主动脉壁的WSS显着低于TAVI前。多变量分析确定通过超声心动图,血小板计数和D-二聚体测量的最大速度是AR10-AUC30的重要决定因素,代表总的血栓形成性。通过改善TAVI后30天的血栓形成活性。临床试验注册:https://clinicaltrials.gov。唯一标识符:NCT03248232。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号